Constructing a safe space for reporting errors is important & enables medical trainees to grow, making them better learners and scholars, and faculty members and patients to express their concerns. During a session at the 2022 ACR Education Exchange, Karina Torralba, MD, MACM, RhMSUS, provided insights into how to manage the barriers to fostering such a workplace culture.
Understanding muscle pathology reports is important to best treat rheumatology patients. Peter Pytel, MD, shared pearls of wisdom specific to the autoimmune inflammatory myopathies and gave a detailed review of what rheumatologists need to know, during the 2022 ACR Education Exchange.
Erin Wilfong, MD, PhD, shared her niche expertise in connective tissue disease ILD (CTD-ILD) via case-based learning during a session of the 2022 ACR Education Exchange.
The growing use of copay accumulator programs, which restrict the application of patient assistance funds toward cost-sharing requirements, hurts patient access to life-changing treatments. This was one topic discussed during the ACR’s Advocacy Leadership Conference in D.C. this May.
Due to its array of radiographic patterns, interstitial lung disease can be challenging to diagnose and treat. Adam Guttentag, MD, a cardiothoracic radiologist, shared tips for ordering and interpreting chest computed tomography.
The ACR’s resolution addressing inappropriate Medicare Administrative Contractor policy processes was adopted, and two co-led resolutions on ARPA-H funding and saline shortages also passed the policy-making body.
Jonathan Hausmann, MD, discussed how active learning techniques, such as the flipped classroom, can increase the effectiveness of medical education and the success of rheumatology fellows.
The ACR’s Committee on Rheumatology Training & Workforce Issues helps young rheumatologists to become successful and find meaning in their work. Here is an update on the committee’s most recent accomplishments.
For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.
NEW YORK (Reuters Health)—Oral synthetic cannabis products that have a high tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio, as well as extracted cannabis products with comparable THC-to-CBD ratios, may provide moderate, short-term improvements in chronic pain, a large systematic review of relevant research suggests.1 However, these products are also associated with higher risks for side effects,…